Skip to main content

Table 4 Multivariate analysis for biochemical progression-free survival

From: The prognostic value of expression of HIF1α, EGFR and VEGF-A, in localized prostate cancer for intermediate- and high-risk patients treated with radiation therapy with or without androgen deprivation therapy

Parameter

HR

(95%CI)

 p 

HR

(95%CI)

 p 

HR

(95%CI)

 p 

PSA

 

0.19

 

0.24

 

0.22

 ≤ 15 ng/ml

1.0

 

1.0

 

1.0

 

 >15 ng/ml

0.55

(0.23–1.33)

 

0.59

(0.25–1.42)

 

0.57

(0.24–1.38)

 

Gleason

 

0.91

 

0.90

 

0.74

 < 7

1.0

 

1.0

 

1.0

 

 ≥ 7

1.04

(0.48–2.27)

 

0.95

(0.44–2.07)

 

1.14

(0.53–2.45)

 

Age

 

0.16

 

0.17

 

0.16

 ≤61 years

1.0

 

1.0

 

1.0

 

 >61 years

1.76

(0.80–3.88)

 

1.73

(0.79–3.79)

 

1.76

(0.80–3.85)

 

HIF1α

 

0.01

    

 ≤ 50%

1.0

     

 >50%

0.37

(0.17–0.82

     

EGFR

   

0.04

  

 negative

  

1.0

   

 Weak or strong

  

(1.03–7.43)

   

VEGF-A

     

0.96

 low

    

1.0

 

 high

    

0.97

(0.39–2.42)

 
  1. PSA prostatic-specific antigen.
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us